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Myasthenia gravis (MG) is an heterogeneous autoimmune disease characterized by the production of autoantibodies against
proteins of the postsynaptic membrane, in the neuromuscular junction. The contribution of genetic factors to MG susceptibility
has been evaluated through family and twin studies however, the precise genetic background of the disease remains elusive. We
conducted a case-control association study in 101 unrelated MG patients of Hellenic origin and 101 healthy volunteers in order to
assess the involvement of common genetic variants in susceptibility to MG. We focused on three candidate genes which have been
clearly associated with several autoimmune diseases, aiming to investigate their potential implication in MG pathogenesis. These
are interferon regulatory factor 5 (IRF-5), TNFα-induced protein 3 (TNFAIP3), also known as A20, and interleukin-10 (IL-10),
key molecules in the regulation of immune function. A statistical trend of association (P = 0.068) between IL-10 promoter single
nucleotide polymorphisms (SNPs) and the subgroups of early and late-onset MG patients was revealed. No statistically significant
diﬀerences were observed in the rest of the variants examined. As far as we are aware, this is the first worldwide attempt to address
the possible association between IRF-5 and TNFAIP3 common genetic variants and the genetic basis of MG.
1. Introduction
Myasthenia gravis (MG) is an organ-specific autoimmune
disease caused by autoantibodies directed against proteins
of the postsynaptic membrane leading to impaired neuro-
muscular transmission. Clinically, MG is characterized by
muscle weakness and rapid fatigue aggravated by exercise
and relieved by rest. The main autoantigen, in 80–90% of
MG patients, is the muscle acetylcholine receptor (AChR),
a pentameric channel which mediates synaptic transduc-
tion at the neuromuscular junction [1]. In several of the
remaining MG patients, autoantibodies to muscle-specific
tyrosine kinase (MuSK) [2] or to lipoprotein-related protein
4 (LRP4) [3] are detected. Both MuSK and LRP4 form
a receptor complex which binds the extracellular matrix
proteoglycan agrin, resulting in AChR clustering, critical for
neuromuscular junction function.
Although MG is a disease that aﬀects both sexes, at all
ages and in all races [4], evidence from several epidemiolog-
ical studies have showed a sex- and age-dependent bimodal
distribution of incidence rate, with one peak in the second
and third decades of life, observed mostly in women, and the
second one in the sixth and seventh decades of life occurring
mainly in men [5]. The above observation led to the
classification of MG into early onset which appears before 50
years of age and is usually related to thymus hyperplasia and
late-onset MG (>50 years) with normal or atrophic thymus.
The extent of genetic contribution to MG susceptibility
has been evaluated through family [6–8] and twin studies
[9], reflective of the disease’s familial clustering and sub-
sequently of genetic inheritance. High concordance rates
of MG observed among monozygotic twins compared with
dizygotic twins strongly suggest the involvement of genetic
factors in the pathogenesis of MG [9]. Moreover, several
studies have reported that MG patients may be aﬀected
with another autoimmune disease, most frequently, thyroid
disorders and rheumatoid arthritis [10]. This finding leads
to the hypothesis that a more generalized disturbance of the
immunological function occurs.
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The human leukocyte antigen (HLA) complex is the
prominent genomic region implicated in MG onset. HLA-
A1 and B8 alleles for class I and DR3 for class II con-
stitute an ancestral haplotype termed “8.1” which has
been reproducibly associated with early onset MG and
thymic hyperplasia [11]. Further research geared towards
the dissection of this extended A1-B8-DR3 haplotype, led
to the identification of the MYAS1 locus, a region of 1.2
Mb encompassing 36 genes, at the boundary of class III and
proximal class I region, thus, excluding the class II loci and
confirming the predominant association of B8 allele over that
of DR3 [12].
Apart from the HLA, a number of HLA-unlinked genetic
loci have also been investigated regarding their involvement
in MG susceptibility. These findings have mainly been
derived by candidate gene studies, while the genes that were
reported to be associated or not associated with MG are
discussed in detail in [13].
Interferon (IFN) regulatory factor 5 (IRF-5) is a member
of the IRF family of transcription factors. IRF-5 is activated
by IFN-α/B and upregulates a set of proinflammatory
cytokines, such as IL-6, TNF-α, and IL-12, while it further
induces IFN gene expression. Results from several studies,
reviewed in [14], have implicated IRF-5 as a susceptibility
gene in SLE. Search for common variants that influence IRF-
5 levels led to the identification of SNP rs10954213 (c.∗555G
> A), located within the polyA+ signal sequence AATAAA in
the 3′ UTR. The G allele disrupts the polyadenylation site and
transcription is terminated far downstream, thus producing
longer and less stable IRF-5 mRNA transcripts [15]. Further,
a 30-bp in-frame insertion-deletion variant (rs60344245) in
the sixth exon of IRF-5 determines the formation of two
families of protein isoforms which have diﬀerential ability to
initiate transcription of IRF-5 target genes [16].
The TNFα-induced protein 3 (TNFAIP3), also known
as A20, is a key molecule in the negative feedback regula-
tion of NF-κB-dependent responses. The inhibitory eﬀect
of TNFAIP3 on NF-κB signaling is generated from the
cooperative activity of its two ubiquitin-editing domains:
the N-terminal ovarian tumor domain (OTU), responsible
for deubiquitinating receptor interacting protein 1 (RIP1),
an essential adaptor protein of the TNF-induced signaling
pathway, and the C-terminal zinc finger-containing domain,
which functions as an E3 ubiquitin ligase promoting the
proteasomal degradation of RIP1 [17].
The SNP rs13207033 (g.137965418G > A), located at
6q23 intergenic region, approximately 185 kb upstream of
TNFAIP3, probably aﬀects gene expression by the presence
of potential regulatory DNA elements [18]. Another study
indicated that a nonsynonymous coding SNP (c.380T > G,
rs2230926) resulting in a phenylalanine-to-cysteine change
at residue 127 (p.F127C), in the OTU domain of the
TNFAIP3 protein, is associated with SLE among individuals
of European ancestry [19].
Interleukin-10 (IL-10) is a pleiotropic cytokine secreted
by diﬀerent cell types, such as T cells and myeloid lineage
cells. IL-10 has been characterized as an anti-inflammatory
cytokine due to its stimulatory eﬀects on TH2 cells [20] and
to the simultaneous suppression of TH1 cells [21]. Moreover,
IL-10 induces proliferation and diﬀerentiation of activated
B lymphocytes [21] leading to further activation of humoral
response. In experimental autoimmune MG (EAMG), IL-10
administration caused the increase of anti-AChR antibody
levels, suggesting a disease-enhancing role of IL-10 [22].
Several variants have been noticed in the 5′ flanking
sequence of the human IL-10 gene. Three SNPs, namely,
rs45552637 (A/C), rs1800872 (T/C), and rs1800896 (A/G),
located at positions −592, −819, and −1082, respectively,
determine the formation of three haplotypes (GCC, ACC,
and ATA). The position of these SNPs is based on the
previously published sequence U16720, deposited in the
EMBL-EBI database. A study by Turner and coworkers
reported correlation of these haplotypes with IL-10 protein
production in vitro [23]. Specifically, GCC/GCC genotype
was associated with high concanavalin A-induced IL-10 pro-
duction, GCC/ACC and GCC/ATA genotypes with medium
and ACC/ACC, ATA/ATA, and ACC/ATA genotypes with low
IL-10 production.
In the current study, a hypothesis-driven approach was
adopted in order to assess the involvement of certain
common variants in MG susceptibility. Thus, we conducted
a candidate gene case-control study, focusing on genes with
a critical role in immune system function, aiming to identify
whether previously reported associations between the above
genes and other autoimmune diseases could hold true for
MG.
2. Materials and Methods
2.1. Study Population. A total of 101 unrelated MG patients,
all of Hellenic descent, were enrolled in this study. Blood
samples from MG patients were collected at the Hellenic
Pasteur Institute during routine diagnostic survey. Only
AChR-positive MG patients were included in our study. The
diagnosis of MG was based on the presence of anti-AChR
antibodies in the patient’s serum, using a radioimmuno-
precipitation assay (RIPA). We intentionally excluded from
the genetic analysis those patients who were identified as
positive for autoantibodies against MuSK, in order to reduce
the heterogeneity of the study group. Although sera of MG
patients were not analyzed for anti-LRP4 autoantibodies, the
absence of this test raises no issue of heterogeneity in the
study population, because of the rare coexistence of anti-
LRP4 and anti-AChR antibodies. The main characteristics
of the anti-AChR MG group (age at onset and gender)
are summarized in Table 1. Written informed consent was
obtained by patients. The control group consisted of 101
ethnically and sex-matched healthy individuals.
2.2. Genotyping. Genomic DNA from each individual was
extracted from peripheral venous blood sample using the
QIAamp Blood Midi kit (Qiagen GmbH, Hilden, Germany).
Polymerase chain reactions (PCRs) were performed with the
KAPA2G Fast HotStart ReadyMix kit (KAPABIOSYSTEMS,
Woburn, MA, USA). Primer sequences are presented in
the supplementary materials as Supplementary Table 1
(see Table 1 in Supplementary Material available online at
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Table 1: Characteristics of the MG study group.
Anti-AChR MG patients (N = 101)
Early onset (n = 45) Late onset (n = 44) Unknown age at onset (n = 12)
Gender (male/female) 8/37 27/17 6/6
Age at onset (mean ± SD) 32.8 ± 8.9 65.8 ± 8.6 —
SD: standard deviation.
doi:10.1155/2012/484919), whereas reaction conditions are
available upon request.
Amplification by PCR and agarose gel electrophoresis
analysis were used to genotype the 30 bp insertion/deletion
variant of IRF5.
PCR-based restriction fragment length polymorphism
(RFLP) assay was used for the detection of SNP rs2230926
(T > G) in TNFAIP3. The amplified fragments of 549 bp
were digested with the restriction enzyme Fnu4HI (New
England Biolabs, Ipswich, MA, USA) and were then analyzed
by electrophoretic separation on 2% w/v agarose gel. The
G allele creates an Fnu4HI restriction site, resulting in the
digestion of amplicons to 319 and 230 bp fragments.
The identification of IL-10 promoter SNPs genotypes was
performed by direct DNA Sanger sequencing. A fragment
of 585 bp, including all three variants, was amplified by
PCR. The PCR products were purified by the column-
based PureLink PCR Purification kit (Invitrogen, Carlsbad,
CA, USA). The sequence of the 585 bp fragment was
determined using the BigDye Terminator chemistry v3.0 kit
on an Applied Biosystems 3730× l DNA sequencer (Applied
Biosystems, Carlsbad, CA, USA). The primers used were the
same as those for the amplification of this region.
Both SNPs, rs10954213 (A/G) in the 3′ UTR of IRF5 and
rs13207033 (G/A) located at a 6q23 intergenic region, were
genotyped by real-time PCR and high resolution melting
curve (HRM) analysis on a RotorGene Q real-time cycler
(Qiagen GmbH, Hilden, Germany). The amplification of the
fragment containing the SNP of interest was carried out
using the Type-it HRM PCR kit (Qiagen GmbH, Hilden,
Germany), according to manufacturer instructions. During
HRM, the temperature increases from 65 to 95◦C, with
a heating rate of 0.1◦C/2 sec, leading to the denaturation
of PCR products and the generation of melting curves,
characteristic for each genotype. Since a single base-pair
change causes a significant shift in the melting temperature
(Tm), genotyping is based on the analysis of the melting
profiles: homozygotes for the A allele exhibit similar melting
profiles and with a lower Tm, compared with the G/G
homozygotes, whereas heterozygotes are diﬀerentiated by a
change in the shape of the melting curve.
No template controls were meticulously included in all
genotyping processes. Negative and positive control samples
were initially identified by DNA sequencing and were,
subsequently, used in all genotyping methods. Each sample
was tested in duplicate, except for those analyzed by PCR-
RFLP and DNA sequencing.
2.3. Statistical Analysis. The diﬀerences in genotype distri-
bution and allele frequencies between cases and controls were
calculated by χ2 analysis or Fisher’s Exact test. P values less
than 0.05 were regarded as statistically significant.
3. Results
Genotype distributions of all variants were consistent with
Hardy-Weinberg equilibrium in both MG patient and con-
trol groups (data not shown).
The allele and genotype frequencies of the IRF-5
rs60344245 variant showed an akin distribution in the
screened groups of 101 MG patients and 100 controls (P =
0.76). Regarding the IRF-5 rs10954213 SNP, A/G genotype
was found to be somewhat more frequent in MG patients
than in controls (54.8% versus 45.5%), but χ2 analysis
revealed no significant diﬀerence (P = 0.3). Allele and
genotype frequencies of both IRF-5 variants are shown in
Table 2.
The TNFAIP3 rs13207033 G/G genotype frequency
showed an increase in healthy controls (44.6%) compared to
MG patients (33.3%). However, statistical analysis did not
indicate any significant diﬀerence between the two groups
(P = 0.17). In the case of rs2230926 coding SNP, genotypes
are distributed similarly in the 73 MG patients and 81
controls examined, as it is inferred by the P value = 0.74.
Genotype frequencies of the rs2230926 variant, in both MG
patients and controls, are in accordance with those derived
from samples of European ancestry (CEU) that are part of
the international HapMap project. In addition, our study
group exhibited rs13207033-genotype frequencies which
are comparable to the frequencies reported in European
populations, in the dbSNP database. Genotyping results of
the two TNFAIP3 variants are summarized in Table 3.
Age of disease onset was also evaluated by dividing MG
patients into early- and late-onset patients. No significant
diﬀerence in genotype distribution was detected between the
two subgroups and the control group (data not shown).
DNA sequence analysis of IL-10 promoter region showed
that the ACC/GCC genotype was the most frequently
observed genotype in both MG patients and controls
(23.72% and 28%, resp.), followed by the low secretion
genotype ATA/ACC, which was detected in 21.62% of total
MG and 18% of controls (Table 4). However, the current
study did not reveal any statistically significant diﬀerence in
IL-10 genotype distribution between the complete cohort of
MG patients (i.e., total MG) and the control group (P =
0.7). Comparison between the subsets according to age at
onset demonstrated that the high IL-10 secretion GCC/GCC
genotype is found in a low frequency in early-onset MG
(4%), while it is overrepresented in late onset MG cases
(20%) (Table 4). A statistical trend of association (P = 0.068)
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Table 2: Genotype and allele distribution of IRF-5 variants in MG patients and controls. Statistical values calculated by χ2 test are also
shown.
IRF-5 variants Control MG Pvalue
rs60344245 N = 100 (%)∗ N = 101 (%)
Genotypes
insertion/insertion 28 (28.0) 24 (23.8)
insertion/deletion 48 (48.0) 53 (52.4) 0.76
deletion/deletion 24 (24.0) 24 (23.8)
Alleles
insertion 104 (52.0) 101 (50.0)
0.76
deletion 96 (48.0) 101 (50.0)
rs10954213 N = 101 (%) N = 84 (%)∗
Genotypes
A/A 37 (36.7) 29 (34.5)
A/G 46 (45.5) 46 (54.8) 0.3
G/G 18 (17.8) 9 (10.7)
Alleles
A 120 (59.0) 104 (62.0)
0.7
G 82 (41.0) 64 (38.0)
∗
Analysis was not successful for a subset of samples.
Table 3: TNFAIP3 genotype and allele frequencies in MG patients and controls. Statistical values calculated by χ2 test are also shown.
TNFAIP3 variants Control MG Pvalue
rs13207033 N = 101 (%) N = 93 (%)∗
Genotypes
G/G 45 (44.6) 31 (33.3)
A/G 44 (43.5) 53 (57.0) 0.17
A/A 12 (11.9) 9 (9.7)
Alleles
G 134 (66.0) 115 (62.0)
0.41
A 68 (34.0) 71 (38.0)
rs2230926 N = 81 (%)∗ N = 73 (%)∗
Genotypes
T/T 77 (95.1) 68 (93.2)
T/G 4 (4.9) 5 (6.8) 0.74
G/G 0 (0.0) 0 (0.0)
Alleles
T 158 (98.0) 141 (97.0)
0.74
G 4 (2.0) 5 (3.0)
∗
Analysis was not successful for a subset of samples.
between the IL-10 phenotype distribution and the two
subgroups of early and late onset was revealed (Figure 1).
4. Discussion
MG is a heterogeneous autoimmune disease with a clear
genetic predisposition. In addition to the HLA loci, sev-
eral common variants in HLA-unlinked genes have been
associated with MG susceptibility [13]. Many of these
risk-associated genes are widely distributed among various
autoimmune diseases, supporting the notion that autoim-
mune diseases are characterized by shared pathogenetic
pathways. In this study, we performed a case-control asso-
ciation study in order to investigate the contribution of
common variants located in IRF-5, TNFAIP3, and IL-10
genes to MG susceptibility. These genes were considered as
good candidates because of their critical role in the regulation
of immune response and their previously known implication
in the autoimmune process [24]. Only patients with anti-
AChR antibodies in their serum were included in the genetic
analysis, as it has been expected that they represent a
more homogenous subset than the broader MG group.
This subgroup was further divided into two distinct disease
entities: early-onsetMG patients, comprisingmostly women,
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Table 4: IL-10 genotype frequencies in the complete cohort of MG patients (i.e., total MG), the subgroups of early and late onset MG and
controls.
Phenotype Genotypes
Total MG
N = 97 (%)a
Early onset
N = 45 (%)b
Late onset
N = 44 (%)b
Control
N = 100 (%)a
High IL-10 expression GCC/GCC 11 (11.32) 2 (4.0) 9 (20.0) 13 (13.0)
Medium IL-10 expression
ACC/GCC 23 (23.72) 12 (27.0) 10 (23.0) 28 (28.0)
ATA/GCC 24 (24.72) 13 (29.0) 9 (20.0) 17 (17.0)
Low IL-10 expression
ACC/ACC 12 (12.42) 5 (11.0) 6 (14.0) 15 (15.0)
ATA/ATA 6 (6.2) 4 (9.0) 2 (5.0) 9 (9.0)
ATA/ACC 21 (21.62) 9 (20.0) 8 (18.0) 18 (18.0)
a
Analysis was not successful for a subset of samples.
bEight MG samples were of unknown age at onset.
0
10
20
30
40
50
60
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IL-10 phenotype distribution 
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Figure 1: IL-10 phenotype distribution in the subgroups of early-
and late-onset MG patients.
and late-onset MG patients, showing a higher proportion of
men.
As far as we are aware, this is the first study, in any
population, to investigate the association between MG and
common variants of IRF-5 and TNFAIP3 genes. According
to previous studies, reviewed in [14], several variants in
the IRF-5 locus have been reproducibly associated with
SLE implicating IRF-5 as a susceptibility gene in lupus.
The rs10954213 SNP has been found to influence mRNA
polyadenylation, thus, impairing the levels of IRF-5 protein;
A/A homozygotes express approximately 5-fold higher levels
of immunoreactive IRF-5 compared to the G/G homozy-
gotes [25]. As for the rs60344245 variant, the deletion of
30 bp (GGCCGCCTACTCTGCAGCCGCCCACTCTGC/−)
removes 10 amino acids from the IRF-5 protein and alters a
proline-, glutamic acid-, serine-, and threonine-rich (PEST)
domain. In the IRF family of proteins, such domains
participate in protein interactions [26] and they also cause
rapid proteolytic degradation [27]. Despite their obvious
functional role, the current study failed to demonstrate a sig-
nificant association of the IRF-5 rs10954213 and rs60344245
variants with MG (P = 0.3 and P = 0.76, resp.), suggesting
that IRF-5 may not be involved in MG pathogenesis.
Furthermore, recent findings from GWA studies have
revealed significant associations between variants in the
human TNFAIP3 locus and a wide spectrum of autoimmune
diseases. A GWA scan of rheumatoid arthritis patients,
with anticitrullinated peptide antibodies, detected strong
evidence of association of the rs13207033 SNP with the
development of RA [28]. Similarly, a study by Musone and
coworkers reported the association of the nonsynonymous
coding SNP, rs2230926 with SLE [19]. Functional studies to
determine the biological impact of rs2230926 demonstrated
that the minor Cys127 protein shows a decreased inhibitory
activity [19]. Yet, lack of association was observed between
MG and TNFAIP3 rs13207033 (P = 0.17) and rs2230926
(P = 0.74) SNPs.
Altogether, our data may indicate that the organ-specific
MG might have a diﬀerent genetic background leading to
its separation from a wide cluster of systemic autoimmune
diseases comprising SLE and RA [29]. An alternative expla-
nation for the lack of association in our study could be
related to the insuﬃcient statistical power owing to relatively
small sample sizes. As it is generally known, common
variants account for a modest proportion of the genetic risk
regarding the autoimmune diseases. In such cases, thousands
of samples may be required in order to detect an association
signal that can be distinguished from the background noise
[30, 31]. However, in low prevalence diseases, such as MG,
the recruitment of large sample sizes is very diﬃcult. It is
worth mentioning that the diagnostic unit of MG in the
Hellenic Pasteur Institute is the only unit in Greece which
has systematically received and analyzed blood samples since
1983. Therefore, our collection of MG DNA samples is
currently the largest in Greece and it is constantly enriched
by new cases.
Moreover, despite the specific selection of anti-AChR
patients and their division into early and late onset, a
further classification according to the thymus anomalies
(thymoma or hyperplasia) could have been informative;
however, histological data were not available.
Finally, an unexpected result was the lack of association
of the IL-10 promoter SNPs with MG. Since these variants
are presumed to lie within the IL-10 promoter region, they
may aﬀect the binding of transcription factors that regulate
IL-10 expression. A recent study by Alseth and cowork-
ers, conducted on the Norwegian population, revealed
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an association of ACC/ACC genotype with the subgroup
of titin antibodies-positive MG patients, while a statistically
significant increased ATA/ATA frequency was observed in
early-onset MG patients [32]. In our group of Hellenic MG
cases, no evidence of association was detected, when we
compared the genotype distribution between the complete
cohort of MG patients and the control group (P = 0.7).
However, GCC/GCC genotype revealed a statistical trend of
association with MG, in the distinct subgroups of early and
late-onset MG patients (P = 0.068). Thus, further studies
in larger sample sizes could uncover possible associations
of MG with IL-10. It is also noteworthy the fact that
allele frequencies for a given SNP may vary substantially
across ethnic groups. The diﬀerence noticed in the frequency
of the ACC/ACC genotype between the Norwegian and
Hellenic control groups (3.4% versus 15%) is reflective of this
condition.
Overall, this has been the first eﬀort, to our knowledge,
to address the possible association between common genetic
variants of IRF-5 and TNFAIP3 and the genetic basis of MG,
in any population, whereas further studies are needed to
unravel the, yet largely unknown, genetic background ofMG.
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